Pharmacologic management of neuropathic pain: Evidence‐based recommendations
By R. Dworkin, Alec B. O’Connor, M. Backonja, John T. Farrar, M. Wallace. Pain, 2007
2,107 citations recorded by the source corpus.
Abstract Patients with neuropathic pain (NP) are challenging to manage and evidence‐based clinical recommendations for pharmacologic management are needed. Systematic literature reviews, randomized clinical trials, and existing guidelines were evaluated at a consensus meeting. Medications were considered for recommendation if their efficacy was supported by at least one methodologically‐sound, randomized clinical trial (RCT) demonstrating superiority to placebo or a relevant comparison treatment. Recommendations were based on the amount and consistency of evidence, degree of efficacy, safety, and clinical experience of the authors. Available RCTs typically evaluated chronic NP of moderate to severe intensity. Recommended first‐line treatments include certain antidepressants (i.e., tricyclic antidepressants and dual reuptake inhibitors of both serotonin and norepinephrine), calcium channel α2‐δ ligands (i.e., gabapentin and pregabalin), and topical lidocaine. Opioid analgesics and tramadol are recommended as generally second‐line treatments that can be considered for first‐line use in select clinical circumstances. Other medications that would generally be used as third‐line treatments but that could also be used as second‐line treatments in some circumstances include certain antiepileptic and antidepressant medications, mexiletine, N‐methyl‐d‐aspartate receptor antagonists, and topical capsaicin. Medication selection should be individualized, considering side effects, potential beneficial or deleterious effects on comorbidities, and whether prompt onset of pain relief is necessary. To date, no medications have demonstrated efficacy in lumbosacral radiculopathy, which is probably the most common type of NP. Long‐term studies, head‐to‐head comparisons between medications, studies involving combinations of medications, and RCTs examining treatment of central NP are lacking and should be a priority for future research.
Subfields: Anesthesiology and Pain Medicine, Cognitive Neuroscience, Physiology
View Paper: https://www.semanticscholar.org/paper/b9b68b9429002c34400308398a1c2c9be08480af
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Anesthesiology and Pain Medicine
In Cognitive Neuroscience
In Physiology
Citations in the corpus
- Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (2017, background): “Based on predicted and observed pharmacokinetic data in those with depression, CYP2D6 ultrarapid metabolizers may be at an increased risk of failing amitriptyline therapy for neuropathic pain due to lower than expected drug concentrations, and thus alternative agents should be considered (32).”
- Neuropathic Pain (2009, background): “Drugs that attenuate central sensitization by acting on calcium channel subunits to decrease transmitter release and on NMDA channels to reduce transmitter action (Chizh et al. 2007; Jorum et al. 2003) are effective treatment options in neuropathic pain (Dworkin et al. 2007).”
- Diabetic Neuropathy: A Position Statement by the American Diabetes Association (2016, methodology): “covered in other literature (15,109), and a simple algorithm for clinical practice use is shown in Fig.”
- The evidence for pharmacological treatment of neuropathic pain (2010, background): “, [26]) have added other aspects based mainly on consensus statements.”
- Pharmacological management of persistent pain in older persons. (2009, background): “Controlled trials have established the efficacy of various opioids in the treatment of persistent pain associated with musculoskeletal conditions, including osteoarthritis(98) and low back pain,(99,100) and in the management of several neuropathic pain conditions, such as diabetic peripheral neuropa”
- EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision (2010, background): “Results: Most large RCTs included patients with diabetic polyneuropathies and postherpetic neuralgia, while an increasing number of smaller studies explored other conditions.”